List of Excipients in Branded Drug NEUPOGEN

Neupogen Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Neupogen, Amgen’s filgrastim product, uses a relatively simple formulation based on sodium acetate, sorbitol, polysorbate 80 and water for injection. The commercial opportunity is not a novel-excipient claim around the legacy product. It is the development of robust, low-impurity excipient systems for biosimilar filgrastim, prefilled syringes, device-compatible presentations, supply-chain resilience and differentiated administration formats.

What excipients are used in Neupogen?

Neupogen is a recombinant methionyl human granulocyte colony-stimulating factor, or filgrastim. The U.S. prescribing information identifies sodium acetate, sorbitol, polysorbate 80 and water for injection as formulation components.[1]

Component	Primary formulation function	Strategic relevance
Sodium acetate	Buffering and pH control	Controls protein charge, solubility and degradation pathways
Sorbitol	Tonicity adjustment and stabilizing excipient	Helps maintain solution properties and may reduce stress during storage
Polysorbate 80	Surfactant	Limits interfacial adsorption and agitation-induced aggregation
Water for injection	Vehicle	Determines ionic environment, bioburden control and container compatibility

The Neupogen formulation is preservative-free and supplied as a sterile injectable product. Its simplicity reduces formulation complexity but increases the importance of raw-material quality, surfactant control, container closure performance and cold-chain handling.

How does Neupogen’s formulation work?

Neupogen is an aqueous protein formulation that must maintain filgrastim’s higher-order structure during manufacturing, filling, transport and administration. The formulation has three primary control objectives.

First, the acetate buffer maintains an acidic formulation environment. Filgrastim stability depends on pH because pH affects protein charge, solubility, aggregation and chemical degradation.

Second, sorbitol provides tonicity and acts as a stabilizing polyol. It can reduce the impact of some thermal and osmotic stresses, although it does not eliminate aggregation or oxidation risk.

Third, polysorbate 80 reduces adsorption at air-liquid and liquid-solid interfaces. This is important for a protein product handled in vials, syringes, infusion systems and, potentially, autoinjector components.

The formulation must also control:

• Protein aggregation
• Subvisible and visible particles
• Oxidation
• Deamidation
• Surface adsorption
• Silicone-oil interactions in prefilled syringes
• Extractables and leachables
• Freeze-thaw damage
• Agitation sensitivity
• Polysorbate degradation and peroxide formation

The key development challenge is that a formulation can meet initial release specifications while degrading during shipping or administration. Excipient strategy therefore has to be linked to container closure, device components and distribution conditions.

What formulation attributes create commercial opportunities?

The main opportunity is not adding more excipients. It is improving the quality and consistency of the existing excipient system.

Low-peroxide polysorbate 80

Polysorbate 80 can contain or generate peroxide species that increase protein oxidation. Oxidative impurities may vary by supplier, manufacturing process, storage history and packaging. A biosimilar developer can create value through:

• Tighter peroxide specifications
• Supplier qualification across multiple manufacturing sites
• Controlled storage and nitrogen protection
• Improved analytical testing
• Lot-to-lot comparability
• Compatibility testing with syringe and infusion materials

A supplier that can provide consistent, low-peroxide polysorbate 80 with a strong regulatory package may gain preferred status with filgrastim manufacturers.

High-purity sorbitol

Sorbitol is a widely available excipient, so it is unlikely to create durable standalone exclusivity. Commercial differentiation can still arise from:

• Low-endotoxin grades
• Low bioburden material
• Defined impurity profiles
• Stable supply from multiple qualified sites
• Reduced variability in osmolality and fill-finish performance

For a biosimilar, sorbitol should be evaluated with the full protein and container system rather than as an isolated component.

Alternative surfactant systems

Polysorbate 20, poloxamers and other surfactants may provide alternatives in selected development programs. Replacing polysorbate 80 could reduce a particular oxidation or compatibility risk, but it creates regulatory and comparability burdens.

A changed surfactant system may affect:

• Protein aggregation
• Subvisible particles
• Immunogenicity risk
• Syringe compatibility
• Extractables and leachables
• Freeze-thaw performance
• Administration through infusion tubing
• Analytical comparability to the reference product

For a biosimilar, a formulation change is commercially attractive only if it provides a measurable advantage without creating a clinically meaningful difference. The FDA’s biosimilar framework focuses on demonstrating high similarity and no clinically meaningful differences from the reference product.[2]

Buffer optimization

A different buffer, including histidine or phosphate, could improve a specific degradation profile. It may also change protein charge, osmolality, aggregation behavior and interaction with packaging materials.

Buffer optimization has more potential for formulation patenting than the use of standard sorbitol alone. Claims could focus on:

• Specific pH ranges
• Excipient concentration windows
• Stability under defined temperatures
• Reduced aggregation after agitation
• Compatibility with a particular syringe or device
• Improved in-use stability

The practical value depends on whether the resulting formulation is sufficiently differentiated from published formulations and whether it avoids blocking patents.

What formulations are protected by Neupogen patents?

Neupogen’s historical product protection centered primarily on filgrastim and related biologic rights rather than a broad, modern excipient platform. The original U.S. patent estate has largely aged out, and current competition is governed mainly by biologic regulatory pathways, manufacturing know-how, device rights and supply execution.

Biologics are not listed in the Orange Book in the same manner as small-molecule drugs. Reference biologics and biosimilars are listed in the FDA Purple Book.[3] A biosimilar applicant does not use the standard Hatch-Waxman Paragraph IV process applicable to small-molecule abbreviated new drug applications.

The commercially relevant IP categories are:

IP category	Relevance to filgrastim
Composition of matter	Historical protection for recombinant G-CSF or filgrastim-related subject matter
Formulation	Buffer, surfactant, stabilizer, concentration and pH combinations
Manufacturing	Host cell, expression, purification, refolding and process controls
Container closure	Syringe, vial, stopper, silicone oil and device compatibility
Method of use	Neutropenia prevention, chemotherapy support, stem-cell mobilization and related uses
Device	Prefilled syringe, automatic injection and administration systems
Trade secrets	Cell banks, purification parameters, impurity control and scale-up methods

A commercial entrant should not assume that the absence of an Orange Book listing means the product has no enforceable IP. Biologic manufacturing and device rights can remain relevant after core molecule patents expire.

When does Neupogen lose exclusivity?

Neupogen has already lost practical U.S. market exclusivity to biosimilar and competing filgrastim products. The FDA approved Zarxio, filgrastim-sndz, as the first U.S. biosimilar to Neupogen in 2015.[4] Nivestym, filgrastim-aafi, followed in 2018, and Releuko, filgrastim-ayow, was approved in 2022.[5,6]

Granix, or tbo-filgrastim, is a related G-CSF product but is not a biosimilar to Neupogen. It received FDA approval through a biologics application before the current biosimilar competition developed.[7]

Product	Active ingredient	Relationship to Neupogen	U.S. approval
Neupogen	Filgrastim	Reference biologic	1991
Granix	Tbo-filgrastim	Stand-alone related G-CSF	2012
Zarxio	Filgrastim-sndz	Biosimilar to Neupogen	2015
Nivestym	Filgrastim-aafi	Biosimilar to Neupogen	2018
Releuko	Filgrastim-ayow	Biosimilar to Neupogen	2022

The commercial question is no longer whether generic entry is possible. It is whether a supplier can compete on acquisition cost, hospital contracting, product availability, administration format and evidence supporting interchangeability.

Which companies are challenging Neupogen commercially?

The U.S. filgrastim market includes Amgen, Sandoz, Pfizer and Coherus-linked commercial operations. Competition also comes from related G-CSF products and from manufacturers supplying hospital and specialty-pharmacy channels.

The principal competitive pressures are:

• Lower biosimilar acquisition prices
• Contracting with integrated delivery networks
• Hospital formulary placement
• Reliable supply during chemotherapy cycles
• Availability of prefilled syringes
• Payer preference for interchangeable products
• Reduced administration and inventory costs

Biosimilar filgrastim products may use a formulation close to the reference product to simplify comparability. Others may seek product differentiation through packaging, device configuration, supply reliability or interchangeability status rather than through excipient novelty.

What is the FDA regulatory status of Neupogen and its biosimilars?

Neupogen is an FDA-approved biologic for reducing the duration of neutropenia and related complications in specified oncology and transplantation settings. Its label includes uses associated with cytotoxic chemotherapy, acute myeloid leukemia, myeloablative therapy followed by bone marrow transplantation, severe chronic neutropenia and peripheral blood progenitor-cell collection.[1]

A filgrastim biosimilar must establish biosimilarity under section 351(k) of the Public Health Service Act. The FDA evaluates analytical similarity, nonclinical data and clinical evidence appropriate to the residual uncertainty.[2]

Interchangeability is a separate designation. A biosimilar may be approved without being interchangeable. Interchangeability can affect pharmacy substitution, payer protocols and commercial uptake, depending on state law and contracting practices.

What does the Orange Book status mean?

The Orange Book is not the primary source for Neupogen patent or exclusivity analysis because Neupogen is a biologic. The Purple Book is the relevant FDA database for reference biologics, biosimilars and interchangeability information.[3]

Paragraph IV certification is therefore not the standard route for challenging Neupogen. Patent disputes may instead arise under the Biologics Price Competition and Innovation Act, including the statutory information-exchange process commonly called the patent dance, declaratory-judgment actions and conventional patent litigation.

What patent litigation affected Neupogen competition?

The major U.S. dispute involved Sandoz’s biosimilar application for Zarxio and Amgen’s patent enforcement strategy. In Sandoz Inc. v. Amgen Inc., the U.S. Supreme Court held in 2017 that the BPCIA’s information exchange was not enforceable through an injunction under federal law and that an applicant could provide the statutory notice of commercial marketing before FDA approval.[8]

The case affected the timing and structure of biosimilar litigation. It did not create a new excipient exclusivity period for Neupogen. For future filgrastim entrants, the practical litigation risks are more likely to involve:

• Manufacturing patents
• Cell-line or host-cell rights
• Purification processes
• Formulation claims
• Prefilled syringe and device patents
• Interchangeability-related commercial disputes
• Contracting and supply arrangements

How strong is the Neupogen excipient patent estate?

The excipient estate is likely to be weaker than the manufacturing and product-specific estate because sodium acetate, sorbitol and polysorbate 80 are established pharmaceutical ingredients. A claim directed only to their presence would face substantial novelty and obviousness risks.

The stronger patent opportunities are narrower combination claims supported by comparative data. Potential claim themes include:

1. A defined filgrastim concentration with a specified acetate concentration and pH range.
2. A low-peroxide polysorbate 80 system that reduces oxidation during storage.
3. A formulation that limits aggregation after defined agitation or temperature excursions.
4. A composition optimized for a silicone-oil-containing prefilled syringe.
5. A formulation with extended in-use stability after syringe removal from refrigeration.
6. A device and formulation combination that reduces protein adsorption or particle formation.
7. A manufacturing process that produces a defined impurity or aggregate profile.

Patent strength will depend on unexpected results, clear analytical differentiation and adequate support across the claimed concentration ranges. A broad claim to a conventional filgrastim formulation is less defensible than a claim tied to a demonstrated stability or device-compatibility benefit.

What generic entry risks exist for Neupogen?

The principal entry risks are commercial and technical rather than basic molecule exclusivity.

Manufacturing risk

Filgrastim manufacturing requires control of expression, purification, refolding or recovery, aggregation and host-cell impurities. A low-cost formulation cannot compensate for inconsistent active-substance quality.

Excipient risk

Polysorbate variability, peroxide formation and supplier changes can create comparability problems. A change in excipient source may require bridging studies and regulatory documentation.

Device risk

Prefilled syringes introduce risks from silicone oil, tungsten residues, needle adhesives, elastomer components and extractables. These risks can affect particles, visible defects and protein stability.

Supply risk

Filgrastim is used in time-sensitive oncology treatment. Hospitals may value reliable supply more than a small unit-price reduction. Dual sourcing and validated alternate excipient suppliers can support contracting.

Regulatory risk

A formulation that departs materially from Neupogen may require more extensive characterization and clinical justification. A product that is too similar to the reference may have limited differentiation and pricing power.

What commercial opportunities exist for excipient suppliers?

Excipient companies can pursue four practical opportunities.

1. Qualified polysorbate supply

A supplier can differentiate through low-peroxide material, tighter oxidation specifications, improved packaging and documented control of degradation products.

2. Formulation development services

Contract development organizations can offer filgrastim formulation screening focused on:

• pH and buffer selection
• Surfactant concentration
• Agitation stability
• Freeze-thaw robustness
• Syringe compatibility
• In-use stability
• Shipping excursion performance

3. Device-compatible excipient systems

The highest-value opportunity may be the combined formulation-container system. A formulation that performs well in a vial may fail in a siliconized syringe. Excipient and device companies can collaborate on an integrated product rather than selling ingredients separately.

4. Biosimilar lifecycle extensions

Commercial extensions may include:

• Lower-volume presentations
• Prefilled syringes
• Autoinjector-compatible formats
• Home-administration products
• Packaging that reduces cold-chain excursions
• Hospital-ready multipacks
• Presentations optimized for stem-cell mobilization

These opportunities are subject to FDA requirements and may require new device, usability, stability or combination-product evidence.

How does Neupogen compare with competing G-CSF products?

Product class	Main advantage	Excipient opportunity	Commercial constraint
Neupogen reference product	Established clinical history	Legacy formulation optimization and supply	Mature product with biosimilar price pressure
Filgrastim biosimilars	Lower cost and established regulatory pathway	Similarity-focused formulation and device execution	Contracting and interchangeability competition
Tbo-filgrastim	Separate product identity	Independent formulation and lifecycle strategy	Not a filgrastim biosimilar
Pegfilgrastim	Longer dosing interval	Long-acting formulation and device systems	Different clinical and patent landscape
Short-acting filgrastim in prefilled syringes	Flexible dosing and home administration	Syringe compatibility and usability	Device and cold-chain requirements

What licensing and partnering opportunities exist?

The most credible licensing opportunities relate to enabling technology rather than a basic Neupogen formulation copy. Potential assets include:

• Low-oxidation polysorbate platforms
• Protein-stabilizing excipient combinations
• Prefilled syringe compatibility technology
• Autoinjector delivery systems
• Manufacturing processes that reduce aggregates
• Analytical methods for surfactant degradation
• Cold-chain excursion protection
• Alternate-source excipient qualification packages

A licensing deal is more defensible when the asset produces a measurable reduction in failure risk, improves shelf life, supports a differentiated presentation or lowers manufacturing cost. A conventional acetate-sorbitol-polysorbate formulation without comparative stability data is unlikely to command strong licensing economics.

Key Takeaways

• Neupogen uses sodium acetate, sorbitol, polysorbate 80 and water for injection.
• The strongest excipient opportunity is quality and performance control, especially for polysorbate 80.
• Low-peroxide surfactants, syringe compatibility and agitation stability are commercially relevant development targets.
• Neupogen has already faced U.S. biosimilar competition from Zarxio, Nivestym and Releuko.
• Neupogen is a biologic, so the Purple Book and BPCIA govern biosimilar and patent analysis rather than the Orange Book and standard Paragraph IV process.
• Broad claims to conventional excipients are weak; narrower claims supported by unexpected stability or device data are stronger.
• Commercial differentiation is most likely through supply reliability, prefilled syringes, home administration, interchangeability and manufacturing efficiency.
• Manufacturing know-how, container closure performance and excipient quality may create greater barriers than legacy formulation patents.

FAQs

Can polysorbate 80 be replaced in a filgrastim biosimilar?

Yes. A developer may evaluate polysorbate 20, poloxamers or other surfactants, but the replacement must support analytical similarity, stability, safety and container compatibility.

Is sorbitol in Neupogen patent-protected?

Sorbitol itself is not a proprietary Neupogen asset. A specific filgrastim formulation containing sorbitol could be claimed if the combination and performance data satisfy patentability requirements.

Can an excipient supplier patent a low-peroxide polysorbate 80 formulation?

Potentially. Patentability would depend on the claimed composition, impurity profile, manufacturing process and evidence of an unexpected benefit over conventional polysorbate 80.

Are Neupogen prefilled syringes combination products?

A prefilled syringe presentation combines a biologic with a delivery system. Regulatory treatment depends on the product configuration and the extent to which the device affects administration, safety or product performance.

What is the best commercial entry strategy for a new filgrastim manufacturer?

The strongest strategy combines a competitive biosimilar or related G-CSF product with reliable supply, a device-compatible formulation, qualified excipient sources and a differentiated hospital or home-administration presentation.

References

1. U.S. Food and Drug Administration. (2023). Neupogen (filgrastim) prescribing information.
2. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry.
3. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products.
4. U.S. Food and Drug Administration. (2015). FDA approves first biosimilar product, Zarxio.
5. U.S. Food and Drug Administration. (2018). FDA approves biosimilar filgrastim-aafi, Nivestym.
6. U.S. Food and Drug Administration. (2022). FDA approves biosimilar filgrastim-ayow, Releuko.
7. U.S. Food and Drug Administration. (2012). Granix (tbo-filgrastim) approval announcement and prescribing information.
8. Supreme Court of the United States. (2017). Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664.